检索结果-南通市图书馆

Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23-Valent Pneumococcal Polysaccharide Vaccine: An Open-Label Trial

引用

World Journal of Vaccines 2013年第4期3卷 123-129页

作者： tino F. schwarz Karlis Pauksens Christine Juergens Deepthi Jayawardene Daniel A. Scott William C. Gruber Beate Schmoele-Thoma Central Laboratory and Vaccination Centre Stiftung Juliusspital Würzburg Germany Department of Medical Sciences Section of Infectious Diseases Uppsala University Akademiska Sjukhuset Uppsala Sweden Pfizer Inc. Collegeville USA Pfizer Pharma GmbH Berlin Germany Pfizer Vaccine Research Pfizer Pearl River USA

An open-label, multicenter study was conducted to describe the safety of the 13-valent pneumococcal conjugate vaccine (PCV13) in 1049 individuals aged ≥68 years, who had previously been immunized with the unconjugated 23-valent pneumococcal polysaccharide vaccine (PPSV23). In addition, the safety profile of PCV13 in this study was compared, in a post-hoc descriptive analysis, to that observed in other elderly populations, who had received PCV13 or PPSV23 as part of other completed studies. Local (56.6%) and systemic reactions (58.4%) were very common, but were mainly mild, and of short duration (mean: 1.3 - 4.6 days). There were no related serious adverse events (AEs) within 1 month after PCV13. 123 days after PCV13 and 94 days after a nonstudy influenza vaccine, a case of transient Guillain-Barré syndrome occurred, which the investigator assessed as possibly related to the vaccination. Reactogenicity observed in this study population was generally similar to that of other elderly study populations with PPSV23-preimmunized adults, and with PPSV23-naive adults. Reactogenicity was less common in this study than that observed in PPSV23-preimmunized adults who were revaccinated with PPSV23 rather than a subsequent dose of PCV13. There were no related serious AEs reported after PCV13 and PPSV23 in these comparator studies. Conclusion: PCV13 may be administered safely to older adults previously immunized with PPSV23. (ClinicalTrials. gov Identifier: NCT00500266)

关键词： 13-Valent Pneumococcal Conjugate Vaccine 23-Valent Pneumococcal Polysaccharide Vaccine Streptococcus pneumoniae Reactogenicity Safety

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Induction of Cervical Mucosal HPV IgG in Women 15-55 Years Old Following Systemic Vaccination with GSKs prophylactic Cervical Cancer Candidate Vaccine

Induction of Cervical Mucosal HPV IgG in Women 15-55 Years O...

引用

24th International Papillomavirus Conference and Clinical Workshop

作者： Sylviane Poncelet Pierre Cambron Sandra Giannini Brigitte Colau Franris Dessy Toufik Zahaf Ligia Pinto Karin Hardt tino schwarz Jacek Wysocki Marek Spaczynski Dominique Descamps GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals GlaxoSmithKline Biologicals National Cancer Institute GlaxoSmithKline Biologicals Stiftung Juliusspital Wuerzburg University of Medical Sciences Katedra Ginekologii Poloznictwa GlaxoSmithKline Biologicals

＜正＞Objectives:We have previously demonstrated that the HPV-16/18 AS04 vaccine candidate,provides a high level of efficacy against HPV-16/18 related cervical intraepithelial neoplasia（grade 2/3）,and sustained HPV-16/18 antibody levels up to 5.5 years In women 15-55 years old,we evaluated in cervico-vaginal secretions（CVS）the vaccine-induced HPV-16/18 immune responses[GSK 105879/014].

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：